Headquartered in Emeryville, CA Fiscal year ends December NASDAQ: BIOA bioagelabs.com
BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging. Its lead product candidate, BGE-102, is a potent, orally bioavailable, brain-penetrant small-molecule NLRP3 inhibitor being developed for diseases driven by inflammation, including retinal diseases such as diabetic macular edema. BGE-102 has completed a Phase 1 SAD/MAD trial and is now in Phase 2 proof-of-concept testing. The company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge leverages a proprietary discovery platform built on human longevity data to address key pathways involved in metabolic aging. The company has active research collaborations with Novartis and Lilly ExploR&D, and an option agreement with JiKang Therapeutics for a novel APJ agonist antibody. Updated
Pre-Market Stock Futures: Futures are trading mixed on Wednesday, after a rough day for technology stocks and the Nasdaq. The combination of the prospect of a longer struggle with Iran, and higher…
BioAge Labs is a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging.
The Wall Street consensus 12-month price target for BIOA is $32.56.
